TY - JOUR
T1 - Bioreducible Hydrophobin-Stabilized Supraparticles for Selective Intracellular Release
AU - Maiolo, Daniele
AU - Pigliacelli, Claudia
AU - Sánchez Moreno, Paola
AU - Violatto, Martina Bruna
AU - Talamini, Laura
AU - Tirotta, Ilaria
AU - Piccirillo, Rosanna
AU - Zucchetti, Massimo
AU - Morosi, Lavinia
AU - Frapolli, Roberta
AU - Candiani, Gabriele
AU - Bigini, Paolo
AU - Metrangolo, Pierangelo
AU - Baldelli Bombelli, Francesca
PY - 2017/9/26
Y1 - 2017/9/26
N2 - One of the main hurdles in nanomedicine is the low stability of drug-nanocarrier complexes as well as the drug delivery efficiency in the region-of-interest. Here, we describe the use of the film-forming protein hydrophobin HFBII to organize dodecanethiol-protected gold nanoparticles (NPs) into well-defined supraparticles (SPs). The obtained SPs are exceptionally stable in vivo and efficiently encapsulate hydrophobic drug molecules. The HFBII film prevents massive release of the encapsulated drug, which, instead, is activated by selective SP disassembly triggered intracellularly by glutathione reduction of the protein film. As a consequence, the therapeutic efficiency of an encapsulated anticancer drug is highly enhanced (2 orders of magnitude decrease in IC50). Biodistribution and pharmacokinetics studies demonstrate the high stability of the loaded SPs in the bloodstream and the selective release of the payloads once taken up in the tissues. Overall, our results provide a rationale for the development of bioreducible and multifunctional nanomedicines.
AB - One of the main hurdles in nanomedicine is the low stability of drug-nanocarrier complexes as well as the drug delivery efficiency in the region-of-interest. Here, we describe the use of the film-forming protein hydrophobin HFBII to organize dodecanethiol-protected gold nanoparticles (NPs) into well-defined supraparticles (SPs). The obtained SPs are exceptionally stable in vivo and efficiently encapsulate hydrophobic drug molecules. The HFBII film prevents massive release of the encapsulated drug, which, instead, is activated by selective SP disassembly triggered intracellularly by glutathione reduction of the protein film. As a consequence, the therapeutic efficiency of an encapsulated anticancer drug is highly enhanced (2 orders of magnitude decrease in IC50). Biodistribution and pharmacokinetics studies demonstrate the high stability of the loaded SPs in the bloodstream and the selective release of the payloads once taken up in the tissues. Overall, our results provide a rationale for the development of bioreducible and multifunctional nanomedicines.
KW - drug release
KW - gold nanoparticle
KW - hydrophobin
KW - nanobio interface
KW - self-assembly
KW - supraparticle
UR - http://www.scopus.com/inward/record.url?scp=85029915850&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85029915850&partnerID=8YFLogxK
U2 - 10.1021/acsnano.7b04979
DO - 10.1021/acsnano.7b04979
M3 - Article
AN - SCOPUS:85029915850
VL - 11
SP - 9413
EP - 9423
JO - ACS Nano
JF - ACS Nano
SN - 1936-0851
IS - 9
ER -